ABIVAX Société Anonyme (ABVX.PA)
EUR 6.49
(0.15%)
EUR 6.49
(0.15%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 44.69 Million EUR | 22.21% |
| 2022 | 36.57 Million EUR | -15.21% |
| 2021 | 43.13 Million EUR | 51.64% |
| 2020 | 28.44 Million EUR | 63.65% |
| 2019 | 17.38 Million EUR | 59.47% |
| 2018 | 10.9 Million EUR | 11747.83% |
| 2017 | 92 Thousand EUR | -70.89% |
| 2016 | 316 Thousand EUR | -27.36% |
| 2015 | 435 Thousand EUR | -79.18% |
| 2014 | 2.08 Million EUR | -9.95% |
| 2013 | 2.32 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 73.57 Million EUR | 0.0% |
| 2023 Q2 | 28.23 Million EUR | 0.0% |
| 2023 FY | 44.69 Million EUR | 22.21% |
| 2023 Q4 | 44.69 Million EUR | 0.0% |
| 2022 Q4 | 36.57 Million EUR | 0.0% |
| 2022 Q2 | 38.19 Million EUR | 0.0% |
| 2022 FY | 36.57 Million EUR | -15.21% |
| 2021 FY | 43.13 Million EUR | 51.64% |
| 2021 Q4 | 43.13 Million EUR | 0.0% |
| 2021 Q2 | 23.84 Million EUR | 0.0% |
| 2020 Q4 | 28.44 Million EUR | 0.0% |
| 2020 Q2 | 20.19 Million EUR | 0.0% |
| 2020 FY | 28.44 Million EUR | 63.65% |
| 2019 FY | 17.38 Million EUR | 59.47% |
| 2019 Q2 | 19.48 Million EUR | 0.0% |
| 2019 Q4 | 17.38 Million EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2018 FY | 10.9 Million EUR | 11747.83% |
| 2018 Q4 | 10.9 Million EUR | 0.0% |
| 2017 Q2 | 76 Thousand EUR | 0.0% |
| 2017 FY | 92 Thousand EUR | -70.89% |
| 2017 Q4 | 262 Thousand EUR | 0.0% |
| 2016 Q4 | 316 Thousand EUR | 0.0% |
| 2016 Q2 | 46 Thousand EUR | 0.0% |
| 2016 FY | 316 Thousand EUR | -27.36% |
| 2015 Q2 | 255 Thousand EUR | 0.0% |
| 2015 Q4 | 435 Thousand EUR | 0.0% |
| 2015 FY | 435 Thousand EUR | -79.18% |
| 2014 Q3 | 2089.00 EUR | 0.0% |
| 2014 FY | 2.08 Million EUR | -9.95% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q4 | 2.08 Million EUR | 99922.98% |
| 2013 FY | 2.32 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -3959.673% |
| Adocia SA | 4.54 Million EUR | -884.515% |
| Aelis Farma SA | 2.04 Million EUR | -2082.471% |
| Biophytis S.A. | 3.11 Million EUR | -1336.741% |
| Advicenne S.A. | 15.89 Million EUR | -181.184% |
| genOway Société anonyme | 5.51 Million EUR | -709.831% |
| IntegraGen SA | 642.28 Thousand EUR | -6859.114% |
| Medesis Pharma S.A. | 1.2 Million EUR | -3624.75% |
| Neovacs S.A. | 650 Thousand EUR | -6776.462% |
| NFL Biosciences SA | 39.2 Thousand EUR | -113914.234% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -925.982% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -2180.076% |
| Sensorion SA | 1.24 Million EUR | -3501.951% |
| Theranexus Société Anonyme | 2.46 Million EUR | -1716.421% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -1046.665% |
| TheraVet SA | 1 Million EUR | -4367.024% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -547.22% |
| DBV Technologies S.A. | 4.52 Million USD | -887.561% |
| Genfit S.A. | 62.25 Million EUR | 28.201% |
| GeNeuro SA | 6.49 Million EUR | -588.462% |
| Innate Pharma S.A. | 30.6 Million EUR | -46.035% |
| Inventiva S.A. | 25.61 Million EUR | -74.489% |
| MaaT Pharma SA | 5.42 Million EUR | -723.908% |
| MedinCell S.A. | 52.8 Million EUR | 15.347% |
| Nanobiotix S.A. | 41.66 Million EUR | -7.29% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | -25.879% |
| Poxel S.A. | 40.14 Million EUR | -11.344% |
| GenSight Biologics S.A. | 1.04 Million EUR | -4164.981% |
| Transgene SA | 17 Thousand EUR | -262823.529% |
| Valneva SE | 132.76 Million EUR | 66.335% |